From adaptive licensing to adaptive pathways: Delivering a flexible life‐span approach to bring new drugs to patients

The concept of adaptive licensing (AL) has met with considerable interest. Yet some remain skeptical about its feasibility. Others argue that the focus and name of AL should be broadened. Against this background of ongoing debate, we examine the environmental changes that will likely make adaptive p...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Clin Pharmacol Ther
Päätekijät: Eichler, H‐G, Baird, LG, Barker, R, Bloechl‐Daum, B, Børlum‐Kristensen, F, Brown, J, Chua, R, Del Signore, S, Dugan, U, Ferguson, J, Garner, S, Goettsch, W, Haigh, J, Honig, P, Hoos, A, Huckle, P, Kondo, T, Le Cam, Y, Leufkens, H, Lim, R, Longson, C, Lumpkin, M, Maraganore, J, O'Rourke, B, Oye, K, Pezalla, E, Pignatti, F, Raine, J, Rasi, G, Salmonson, T, Samaha, D, Schneeweiss, S, Siviero, PD, Skinner, M, Teagarden, JR, Tominaga, T, Trusheim, MR, Tunis, S, Unger, TF, Vamvakas, S, Hirsch, G
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: John Wiley and Sons Inc. 2015
Aiheet:
State of the Art
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC6706805/
https://ncbi.nlm.nih.gov/pubmed/25669457
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cpt.59
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia